Shares of Evoke Pharma Inc. (NASDAQ:EVOK) were up 28.9% during mid-day trading on Wednesday . The company traded as high as $2.05 and last traded at $2.05, with a volume of 4,511,934 shares traded. The stock had previously closed at $1.59.

A number of analysts have issued reports on EVOK shares. FBR & Co boosted their price target on shares of Evoke Pharma to $9.00 and gave the stock an “outperform” rating in a research note on Tuesday, July 19th. Rodman & Renshaw lowered shares of Evoke Pharma from a “buy” rating to a “neutral” rating and set a $2.00 price target on the stock. in a research note on Monday, July 18th. Feltl & Co. lowered shares of Evoke Pharma from a “strong-buy” rating to a “sell” rating in a research note on Monday, July 18th. Brean Capital lowered shares of Evoke Pharma from a “buy” rating to a “hold” rating in a research note on Monday, July 18th. Finally, Zacks Investment Research lowered shares of Evoke Pharma from a “buy” rating to a “hold” rating in a research note on Monday, May 16th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating and three have issued a buy rating to the company’s stock. Evoke Pharma presently has an average rating of “Hold” and a consensus target price of $13.34.

The company’s 50-day moving average is $5.96 and its 200 day moving average is $4.74. The company’s market cap is $14.84 million.

Evoke Pharma (NASDAQ:EVOK) last released its quarterly earnings results on Wednesday, May 11th. The specialty pharmaceutical company reported ($0.45) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by $0.04. Equities research analysts anticipate that Evoke Pharma Inc. will post ($1.43) EPS for the current fiscal year.

In related news, major shareholder Parters Vii L. P. Domain sold 344,120 shares of Evoke Pharma stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $4.70, for a total value of $1,617,364.00. The transaction was disclosed in a filing with the SEC, which is available at this link.

Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.